Cognition Therapeutics, Inc. Other Noncash Income (Expense)
Cognition Therapeutics, Inc. (CGTX) reported Other Noncash Income (Expense) of $291.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-07
- Cognition Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $291.00K, a 106.38% increase year-over-year.
- Cognition Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $273.00K, a 27.57% increase year-over-year.
- Cognition Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $334.00K.
- Cognition Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $230.00K, a 2.54% decline year-over-year.
- Cognition Therapeutics, Inc. other noncash income (expense) for fiscal 2025 was $919.00K, a 37.99% increase from fiscal 2024.
- Cognition Therapeutics, Inc. other noncash income (expense) for fiscal 2024 was $666.00K, a 321.52% increase from fiscal 2023.
- Cognition Therapeutics, Inc. other noncash income (expense) for fiscal 2023 was $158.00K.
- Cognition Therapeutics, Inc. other noncash income (expense) for fiscal 2022 was -$35.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $291.00K 10-Q · filed 2026-08-07 | $564.00K 10-Q · filed 2026-08-07 | $898.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.13M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $273.00K 10-Q · filed 2026-05-08 | $607.00K derived: sum of 2 quarters · filed 2026-05-08 | $837.00K derived: sum of 3 quarters · filed 2026-05-08 | $978.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $564.00K derived: sum of 2 quarters · filed 2026-03-26 | $705.00K derived: sum of 3 quarters · filed 2026-08-07 | $919.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $230.00K 10-Q · filed 2025-11-06 | $371.00K derived: sum of 2 quarters · filed 2026-08-07 | $585.00K 10-Q · filed 2025-11-06 | $438.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $141.00K 10-Q · filed 2026-08-07 | $355.00K 10-Q · filed 2026-08-07 | $208.00K derived: sum of 3 quarters · filed 2026-08-07 | $444.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $214.00K 10-Q · filed 2026-05-08 | $67.00K derived: sum of 2 quarters · filed 2026-05-08 | $303.00K derived: sum of 3 quarters · filed 2026-05-08 | $636.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $89.00K derived: sum of 2 quarters · filed 2026-03-26 | $422.00K derived: sum of 3 quarters · filed 2026-03-26 | $666.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $236.00K 10-Q · filed 2025-11-06 | $569.00K derived: sum of 2 quarters · filed 2025-11-06 | $813.00K 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $333.00K 10-Q · filed 2025-08-07 | $577.00K 10-Q · filed 2025-08-07 | $864.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.18M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $244.00K 10-Q · filed 2025-05-07 | $531.00K derived: sum of 2 quarters · filed 2025-05-07 | $845.00K derived: sum of 3 quarters · filed 2025-05-07 | $1.02M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $601.00K derived: sum of 2 quarters · filed 2025-03-20 | $773.00K derived: sum of 3 quarters · filed 2025-03-20 | $158.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $314.00K 10-Q · filed 2024-11-13 | $486.00K derived: sum of 2 quarters · filed 2024-11-13 | -$129.00K 10-Q · filed 2024-11-13 | $18.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $172.00K 10-Q · filed 2024-08-08 | -$443.00K 10-Q · filed 2024-08-08 | -$296.00K derived: sum of 3 quarters · filed 2024-08-08 | -$241.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$615.00K 10-Q · filed 2024-05-07 | -$468.00K derived: sum of 2 quarters · filed 2024-05-07 | -$413.00K derived: sum of 3 quarters · filed 2024-05-07 | -$455.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $202.00K derived: sum of 2 quarters · filed 2024-03-26 | $160.00K derived: sum of 3 quarters · filed 2024-03-26 | -$35.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $55.00K 10-Q · filed 2023-11-02 | $13.00K derived: sum of 2 quarters · filed 2023-11-02 | -$182.00K 10-Q · filed 2023-11-02 | -$526.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$42.00K 10-Q · filed 2023-08-08 | -$237.00K 10-Q · filed 2023-08-08 | -$581.00K derived: sum of 3 quarters · filed 2023-08-08 | -$573.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$195.00K 10-Q · filed 2023-05-04 | -$539.00K derived: sum of 2 quarters · filed 2023-05-04 | -$531.00K derived: sum of 3 quarters · filed 2023-05-04 | -$428.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$336.00K derived: sum of 2 quarters · filed 2023-03-23 | -$233.00K derived: sum of 3 quarters · filed 2023-03-23 | -$88.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $8.00K 10-Q · filed 2022-11-14 | $111.00K derived: sum of 2 quarters · filed 2022-11-14 | $256.00K 10-Q · filed 2022-11-14 | $297.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $103.00K 10-Q · filed 2022-08-09 | $248.00K 10-Q · filed 2022-08-09 | $289.00K derived: sum of 3 quarters · filed 2022-08-09 | $384.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $145.00K 10-Q · filed 2022-05-11 | $186.00K derived: sum of 2 quarters · filed 2022-05-11 | $281.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $136.00K derived: sum of 2 quarters · filed 2022-03-30 | $394.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $95.00K 10-Q · filed 2021-11-17 | $353.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |